Everything below concerns metabolite. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Κ-casein labeled with the fluorochrome fluorescein isothiocyanate (FITC) to yield the fluorescein thiocarbamoyl (FTC) derivative. This substrate is used to determinate the milk clotting activity of proteases. FTC-κ-casein method affords accurate and precise determinations of κ-caseinolytic degradation, the first step in the milk-clotting process. This method is the result of a modification to the one described by S.S. Twining (1984). The main modification was substituting the substrate previously used (casein) by κ-casein labeled with the fluorochrome fluorescein isothiocyanate (FITC) to yield the fluorescein thiocarbamoyl (FTC) derivative. This variation allows quantification of the κ-casein molecules degraded in a more precise and specific way, detecting only those enzymes able to degrade such molecules. The method described by Twining (1984), however, was designed to detect the proteolytic activity of a considerably larger variety of enzymes. FTC-κ-casein allows the detection of different types of proteases at levels when no milk clotting is yet apparent, demonstrating its higher sensitivity over currently used assay procedures. Therefore, the method may find application as an indicator during the purification or characterization of new milk-clotting enzymes.
From April to May 2024, Rio Grande do Sul was hit by massive flooding, which also severely hit Porto Alegre. This was partly seen as, in addition to the sheer amount of precipitation, insufficient pumping of water, as trash and rubble had blocked many manholes in the city. Melo, during the flooding, affirmed that the city government knew that there was a possibility of strong rains and was not taken by surprise. He denied, however, that the city government had delayed its response and put the responsibility on the new round of floodings for the high volume, as well as the population, blaming them for the trash strewn throughout the city. During the floods, the Guaíba hit its highest ever historical level, leaving various parts of the city submerged and many people stranded. Due to the severity of the situation, the municipality set up 21 centers to receive thousands of people who were forced to leave their homes. The flooding was also marked by conflicts between Melo and the federal government, during which he criticized what he saw was the lack of support from them, despite having also delayed a formal emergency request for days. During this period, federal deputy Fernanda Melchionna and city councilman Roberto Robaina, both from PSOL, sued Melo. They both requested that the State Attorney's Office to start an investigation against Melo due to the fact that the municipal government had not sent the federal government the data of families in Porto Alegre hit by the floods.
Though it became a "forgotten drug" following the discovery of antibiotics in 1928, there has been a resurgence in interest in methenamine since 2010 owing to increasing rates of bacterial resistance with antibiotics. Larger and higher-quality clinical trials of methenamine for UTI prevention have started to be published in the 2020s and it may soon be recommended by more medical guidelines. Methenamine has been found to be more cost-effective than low-dose prophylactic antibiotics for preventing UTIs.
===== COVID-19 (no contraindication) ===== In May 2020, WHO and UNICEF stressed that the ongoing COVID-19 pandemic was not a reason to discontinue breastfeeding. They recommend that women continue to breastfeed during the pandemic, even if they have confirmed or suspected COVID-19, because evidence indicates that it is unlikely that COVID-19 can be transmitted through breast milk. A study published in 2021 found that, while SARS-CoV-2 RNA may be found in some samples of breastmilk from recently infected mothers, the breastmilk does not contain infectious virus and is not considered a transmission risk factor. Mothers who have suspected or confirmed diagnoses of COVID-19 should thoroughly wash their hands and wear a well-fitting mask before breastfeeding their infant, or express breastmilk and feed the infant by bottle.
Sources: en.wikipedia.org
In 1960, the SAC Airborne Command Post or "Looking Glass" was initiated, with the conversion of 5 (6 but 1 was reverted ) KC-135A tankers to Airborne Command Posts. In July 1960, operational testing began under the code name Looking Glass, with a SAC general officer always aboard each flight, and operated by the 34th Air Refueling Squadron at Offutt AFB. In August 1966, the mission transferred to the 38th Strategic Reconnaissance Squadron, to the 2nd Airborne Command and Control Squadron in April 1970, to the 7th Airborne Command and Control Squadron in July 1994, and to the USSTRATCOM's Strategic Communications Wing One in October 1998. In February 1961, the Strategic Air Command put Looking Glass mission on continuous airborne alert. Aircraft from the 34th Air Refueling Squadron were based at its headquarters at Offutt AFB, backed up by aircraft flying with the Second Air Force / 913th Air Refueling Squadron at Barksdale AFB, Louisiana, the Eighth Air Force / 99th Air Refueling Squadron at Westover AFB, Massachusetts, and the Fifteenth Air Force / 22d Air Refueling Squadron, March AFB, California. EC-135 Looking Glass aircraft were airborne 24 hours a day for over 29 years, until July 24, 1990, when "The Glass" ceased continuous airborne alert, but remained on ground or airborne alert 24 hours a day. The Looking Glass mission mirrors ground-based command, control, and communications (C3 or C³) located at the USSTRATCOM Global Operations Center (GOC) at Offutt AFB.
Glyn Ford and Jonathan Simnett, Silver from the Sea, September/October 1982, Volume 33, Number 5, Saudi Aramco World Archived 2006-11-12 at the Wayback Machine Accessed 17 October 2005 Ballard, Robert D., 2000, The Eternal Darkness, Princeton University Press. Csotonyi, J. T.; Stackebrandt, E.; Yurkov, V. (4 July 2006). "Anaerobic Respiration on Tellurate and Other Metalloids in Bacteria from Hydrothermal Vent Fields in the Eastern Pacific Ocean". Applied and Environmental Microbiology. 72 (7): 4950–4956. Bibcode:2006ApEnM..72.4950C. doi:10.1128/AEM.00223-06. PMC 1489322. PMID 16820492. Koschinsky, Andrea; Garbe-Schönberg, Dieter; Sander, Sylvia; Schmidt, Katja; Gennerich, Hans-Hermann; Strauss, Harald (2008). "Hydrothermal venting at pressure-temperature conditions above the critical point of seawater, 5°S on the Mid-Atlantic Ridge". Geology. 36 (8): 615. Bibcode:2008Geo....36..615K. doi:10.1130/G24726A.1. Catherine Brahic (4 August 2008). "Found: The hottest water on Earth". New Scientist. Retrieved 18 June 2010.
== Soluble TCR == A soluble TCR is a TCR that has been made water-soluble using protein engineering. Such a protein is based on changing an existing TCR's chains to remove the transmembrane portions, leaving only the extracellular part. A number of techniques from protein engineering are then used to stabilize the complex and improve its binding characteristics. A soluble TCR can be used as an antigen-binding module, much like how monoclonal antibodies are used in medicine. Their advantage over antibodies is that they make use of the MHC/HLA display mechanism, allowing them to detect not only extracellular antigens, but also fragments of intracellular ones. On the other hand, they also face some restrictions in terms of applicable HLA genotypes due to them being made to target the complex of a MHC protein with the antigen fragment. One idea for overcoming this restriction is to instead target monomorphic HLA-like molecules such as HLA-E, MHC-related protein 1 (MR1) and cluster of differentiation 1 a, b, c and d (CD1a, CD1b, CD1c or CD1d). An example of a protein derived from soluble TCR is tebentafusp, approved by the US FDA in 2022. This designed protein contains a soluble TCR (αβ) targeting a fragment of gp100 presented by HLA-A*02:01 connected to a ScFv that binds CD3. As a result it causes T cells to activate in the vicinity of cells that present gp100, acting as a molecular glue (a bi-specific T-cell engager in the broad sense). It is only applicable to people with the HLA-A*02:01 genotype.
=== Early puberty === Anastrozole is used at a dosage of 0.5 to 1 mg/day in combination with the antiandrogen bicalutamide in the treatment of peripheral precocious puberty, for instance due to familial male-limited precocious puberty (testotoxicosis) and McCune–Albright syndrome, in boys.
Cilengitide (EMD 121974) is a molecule designed and synthesized at the Technical University of Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis (forming new blood vessels), and other aspects of tumor biology. Hence, it is under investigation for the treatment of glioblastoma, where it may act by inhibiting angiogenesis, and influencing tumor invasion and proliferation. The European Medicines Agency has granted cilengitide orphan drug status. Cilengitide seems to function by inhibiting the FAK/Src/AKT pathway and inducing apoptosis in endothelial cells. Preclinical studies in mice of cilengitide were able to demonstrate efficacious tumor regression. In a rat xenograft model, cilengitide was able to potentiate the cytotoxic effects of radiation when cilengitide was administered prior to radiation therapy. When combined with radiation, inhibition of integrin expression by cilengitide synergistically improves the cytotoxic effects of ionizing radiation for glioblastoma.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.